Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taylor R Brooks

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Scientific Reports|March 8, 2018
Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitrationJoseph Markowitz, Jiang Wang, Zach Vangundy, et al.
Leukemia|February 17, 2026
Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphomaDaniel J Landsburg, Nancy Musoke, Caren Gentile, et al.
Oncotargets and Therapy|October 13, 2016
MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approachesJoseph Markowitz, Zachary Abrams, Naduparambil K Jacob, et al.
Haematologica|October 30, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-RBrian Hess, Alison Moskowitz, James A Davis, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
Blood|July 15, 2025
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamabTaylor R Brooks, Emily C Zabor, Yohanna Bedelu, et al.
Blood Advances|May 13, 2024
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomasRahul S Bhansali, Fredrik Ellin, Thomas Relander, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Cancer Journal|April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Scientific Reports|March 8, 2018
Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitrationJoseph Markowitz, Jiang Wang, Zach Vangundy, et al.
Leukemia|February 17, 2026
Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphomaDaniel J Landsburg, Nancy Musoke, Caren Gentile, et al.
Oncotargets and Therapy|October 13, 2016
MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approachesJoseph Markowitz, Zachary Abrams, Naduparambil K Jacob, et al.
Haematologica|October 30, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-RBrian Hess, Alison Moskowitz, James A Davis, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
Blood|July 15, 2025
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamabTaylor R Brooks, Emily C Zabor, Yohanna Bedelu, et al.
Blood Advances|May 13, 2024
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomasRahul S Bhansali, Fredrik Ellin, Thomas Relander, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Cancer Journal|April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 2